William Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William Gordon has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Petronela Hanga
Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering University College London London UK
3 shared publications - Michael Sulu
Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering University College London London UK
3 shared publications Alicia Okines
Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK
2 shared publicationsAlison Reid
Uro-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK
2 shared publicationsAna Agua-Doce
Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK
2 shared publicationsAndreas M. Schmitt
Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK
2 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Wiley in Food Bioengineering
- Vol. 5 (3) , 389-404
Under‐Explored Species, Breeds and Cell Types With Potential for Cultivated Meat Production
To achieve scale and cost parity, cultivated meat production must overcome critical bottlenecks such as the quality of starting cells. This review presents a systematic evaluation of unconventional and non‐traditional sources of cells as targeted strategies to address these specific manufacturing challenges. By moving beyond traditional domesticated livestock as sources for starting cells, this review highlights how under‐explored species or breeds offer distinct biological advantages with potential to directly improve bioprocess efficiency by leveraging natural traits such as enhanced proliferation rates, potential for spontaneous immortalisation and optimised differentiation. Furthermore, diversifying cell sourcing not only accelerates the path to commercial‐scale production but also enables the creation of novel cultivated meat products and other high‐value animal‐derived materials.
- 6 September 2026
- Published by Wiley in Food Bioengineering
- Vol. 5 (3) , 389-404
Open AccessUnder‐Explored Species, Breeds and Cell Types With Potential for Cultivated Meat Production
To achieve scale and cost parity, cultivated meat production must overcome critical bottlenecks such as the quality of starting cells. This review presents a systematic evaluation of unconventional and non‐traditional sources of cells as targeted strategies to address these specific manufacturing challenges. By moving beyond traditional domesticated livestock as sources for starting cells, this review highlights how under‐explored species or breeds offer distinct biological advantages with potential to directly improve bioprocess efficiency by leveraging natural traits such as enhanced proliferation rates, potential for spontaneous immortalisation and optimised differentiation. Furthermore, diversifying cell sourcing not only accelerates the path to commercial‐scale production but also enables the creation of novel cultivated meat products and other high‐value animal‐derived materials.
- Open Access
Serum-free media development and validation for cultivation of C2C12 immortalised murine myosatellite cell line for cultivated meat
The development of cost-effective, serum-free media is critical for scalable cultivated meat production. This study used high-throughput screening through a Design of Experiments (DoE) approach to develop an animal-free, serum-free medium (MMM1) specifically for the C2C12 murine myoblasts model cell line with applicability in cultivated meat research including for pet food. Low cost, food-grade inputs such as methylcellulose and spirulina extract resulted in significant cell growth improvements. The optimised MMM1 formulation containing low cost, food-grade inputs, achieved cumulative population doublings comparable to 10% (v/v) fetal bovine serum over four consecutive passages. Furthermore, MMM1 supported scalable cell expansion on commercially available dextran-based microcarriers (Cytodex-3) in both static and agitated conditions in spinner flasks, matching growth rates of serum-based controls. Finally, transitioning to a food-grade DMEM/F12 basal medium maintained cell proliferation equivalent to the pharmaceutical-grade DMEM/F12, but at a significantly lower cost, thus offering a viable strategy to substantially reduce biomanufacturing costs which is a critical challenge in cultivated meat production. Highlights: A serum-free medium formulation for C2C12 murine myoblasts (MMM1) C2C12 growth in MMM1 comparable to serum-based medium C2C12 growth in MMM1 in microcarrier culture as effective as serum-based medium MMM1 can be translated to be animal-free and fully food-grade Graphical
Open AccessSerum-free media development and validation for cultivation of C2C12 immortalised murine myosatellite cell line for cultivated meat
The development of cost-effective, serum-free media is critical for scalable cultivated meat production. This study used high-throughput screening through a Design of Experiments (DoE) approach to develop an animal-free, serum-free medium (MMM1) specifically for the C2C12 murine myoblasts model cell line with applicability in cultivated meat research including for pet food. Low cost, food-grade inputs such as methylcellulose and spirulina extract resulted in significant cell growth improvements. The optimised MMM1 formulation containing low cost, food-grade inputs, achieved cumulative population doublings comparable to 10% (v/v) fetal bovine serum over four consecutive passages. Furthermore, MMM1 supported scalable cell expansion on commercially available dextran-based microcarriers (Cytodex-3) in both static and agitated conditions in spinner flasks, matching growth rates of serum-based controls. Finally, transitioning to a food-grade DMEM/F12 basal medium maintained cell proliferation equivalent to the pharmaceutical-grade DMEM/F12, but at a significantly lower cost, thus offering a viable strategy to substantially reduce biomanufacturing costs which is a critical challenge in cultivated meat production. Highlights: A serum-free medium formulation for C2C12 murine myoblasts (MMM1) C2C12 growth in MMM1 comparable to serum-based medium C2C12 growth in MMM1 in microcarrier culture as effective as serum-based medium MMM1 can be translated to be animal-free and fully food-grade Graphical
- Open Access
Investigations into cyanobacteria, plant, and insect protein extracts as serum-replacement supplements for the expansion of cells for cultivated meat
Cultivated meat has undeniable potential to address some of the current detrimental impacts of animal farming, while addressing food security worldwide. However, one of the main challenges in cultivated meat production is manufacturing cost. The main contributor to cost is the culture media which comprises expensive components such as growth factors and animal-derived proteins. This study investigated alternative, food grade, high protein extracts as serum replacements in serum-free media formulations. The extracts were chosen to represent various sustainable sources of proteins: marine (spirulina e.g. cyanobacterium), plant (faba bean) and insect (mealworm flour). Different processing methods and different solvents were investigated for production of cell culture-compatible extracts which were then tested with mouse myoblasts (C2C12) and primary porcine myosatellites (pMyoSCs). A serum-free medium formulation containing 2.6% v/v spirulina extract was found to support long term growth of C2C12 cells for ∼10 population doublings compared to only ∼2 in the control. The processing steps were optimized, showing that a glycerine solution was best for free amino acid and protein yield (4950 µM total free amino acids, 11.45 mg/mL protein concentration). This solution had a positive effect on C2C12 cells, increasing their growth by up to 20% when added to the B8 medium. However, this benefit did not translate to pMyoSCs, which showed no significant growth increases in short-term screening. This work demonstrates a method for converting food grade protein powders into effective culture media supplements and highlights the potential of spirulina-based extracts for the use in cultivated meat. Abstract Figure: Graphical abstract Created in BioRender. Gordon-Petrovskii, W. (2025) https://BioRender.com/by7khs1
Open AccessInvestigations into cyanobacteria, plant, and insect protein extracts as serum-replacement supplements for the expansion of cells for cultivated meat
Cultivated meat has undeniable potential to address some of the current detrimental impacts of animal farming, while addressing food security worldwide. However, one of the main challenges in cultivated meat production is manufacturing cost. The main contributor to cost is the culture media which comprises expensive components such as growth factors and animal-derived proteins. This study investigated alternative, food grade, high protein extracts as serum replacements in serum-free media formulations. The extracts were chosen to represent various sustainable sources of proteins: marine (spirulina e.g. cyanobacterium), plant (faba bean) and insect (mealworm flour). Different processing methods and different solvents were investigated for production of cell culture-compatible extracts which were then tested with mouse myoblasts (C2C12) and primary porcine myosatellites (pMyoSCs). A serum-free medium formulation containing 2.6% v/v spirulina extract was found to support long term growth of C2C12 cells for ∼10 population doublings compared to only ∼2 in the control. The processing steps were optimized, showing that a glycerine solution was best for free amino acid and protein yield (4950 µM total free amino acids, 11.45 mg/mL protein concentration). This solution had a positive effect on C2C12 cells, increasing their growth by up to 20% when added to the B8 medium. However, this benefit did not translate to pMyoSCs, which showed no significant growth increases in short-term screening. This work demonstrates a method for converting food grade protein powders into effective culture media supplements and highlights the potential of spirulina-based extracts for the use in cultivated meat. Abstract Figure: Graphical abstract Created in BioRender. Gordon-Petrovskii, W. (2025) https://BioRender.com/by7khs1
- Open Access
- 27 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (12) , 1305-1320
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
- 27 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (12) , 1305-1320
Open AccessAdaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
- Open Access
- 27 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (12) , 1321-1337
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
- 27 October 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2 (12) , 1321-1337
Open AccessFunctional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.